Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

BACKGROUND: Pembrolizumab has been shown to improve overall survival (OS) and progression free survival (PFS) compared to ipilimumab in patients with ipilimumab-naïve advanced melanoma; however, there are no published data on the cost-effectiveness for pembrolizumab compared to standard-of-care trea...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cost Eff Resour Alloc
Autores principales: Loong, Herbert H., Wong, Carlos K. H., Leung, Linda K. S., Tan, S. C., Jen, Jason, Lee, Mary Y. K., Aguiar-Ibáñez, Raquel, Wang, Jingshu
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964068/
https://ncbi.nlm.nih.gov/pubmed/31969794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-020-0200-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares